Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589651 · ClinicalTrials.gov registry record · Phase 1
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT03589651 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 83 participants.
The verdict
NCT03589651, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.
Interventions
- DRUG Retifanlimab
- DRUG Epacadostat
- DRUG INCB050465
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2018-08-17 |
| Est. Completion | 2022-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03589651
The ClinicalTrials.gov registry entry for NCT03589651 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Retifanlimab is the first listed.
NCT03589651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03589651 about?
NCT03589651 is a clinical study titled "INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors". The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.
What is the current status of trial NCT03589651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2018-08-17. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT03589651?
The interventions under investigation include: Retifanlimab (DRUG), Epacadostat (DRUG), INCB050465 (DRUG).
Who is sponsoring clinical trial NCT03589651?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.